Blood group isoantigen deletion in carcinoma in situ of the urinary bladder
β Scribed by Ronald S. Weinstein; Joseph Alroy; George M. Farrow; Alexander W. Miller III; Israel Davidsohn
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 816 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. To the authors' knowledge, the long term follow-up of patients with carcinoma in situ of the urinary bladder is limited. ## METHODS. The authors studied 138 patients diagnosed with urothelial carcinoma in situ of the bladder at the Mayo Clinic between 1972-1979. All the histologi
In the United States, nearly all cases of bladder cancer are of the transitional cell type, and epidemiological evidence indicates that among these, approximately 80% present initially as more or less well-differentiated, superficial papillary neoplasms with a tendency for multifocal or diffuse invo
## Abstract Bladder cancer develops through different pathways, provisionally entitled βpapillaryβ and βinvasive.β Carcinoma __in situ__ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these clinically important lesions, and